1. Home
  2. EXFY vs MOLN Comparison

EXFY vs MOLN Comparison

Compare EXFY & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Expensify Inc.

EXFY

Expensify Inc.

HOLD

Current Price

$1.13

Market Cap

132.1M

Sector

Technology

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

HOLD

Current Price

$3.84

Market Cap

144.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
EXFY
MOLN
Founded
2008
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
132.1M
144.0M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
EXFY
MOLN
Price
$1.13
$3.84
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$4.50
$8.38
AVG Volume (30 Days)
640.8K
2.0K
Earning Date
05-07-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$142,101,000.00
N/A
Revenue This Year
$0.42
N/A
Revenue Next Year
$0.11
$374.07
P/E Ratio
N/A
N/A
Revenue Growth
2.06
N/A
52 Week Low
$0.69
$3.41
52 Week High
$2.55
$5.36

Technical Indicators

Market Signals
Indicator
EXFY
MOLN
Relative Strength Index (RSI) 62.63 35.66
Support Level $0.76 $3.52
Resistance Level $1.16 $3.97
Average True Range (ATR) 0.07 0.08
MACD 0.01 -0.04
Stochastic Oscillator 79.34 5.09

Price Performance

Historical Comparison
EXFY
MOLN

About EXFY Expensify Inc.

Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay and travel booking in one app.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.

Share on Social Networks: